These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1303 related articles for article (PubMed ID: 29615399)

  • 21. Folate receptor 1 (FOLR1) targeted chimeric antigen receptor (CAR) T cells for the treatment of gastric cancer.
    Kim M; Pyo S; Kang CH; Lee CO; Lee HK; Choi SU; Park CH
    PLoS One; 2018; 13(6):e0198347. PubMed ID: 29874279
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Adoptive T-cell therapy of prostate cancer targeting the cancer stem cell antigen EpCAM.
    Deng Z; Wu Y; Ma W; Zhang S; Zhang YQ
    BMC Immunol; 2015 Jan; 16(1):1. PubMed ID: 25636521
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combination Therapy with EpCAM-CAR-NK-92 Cells and Regorafenib against Human Colorectal Cancer Models.
    Zhang Q; Zhang H; Ding J; Liu H; Li H; Li H; Lu M; Miao Y; Li L; Zheng J
    J Immunol Res; 2018; 2018():4263520. PubMed ID: 30410941
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Eradication of Hepatocellular Carcinoma by NKG2D-Based CAR-T Cells.
    Sun B; Yang D; Dai H; Liu X; Jia R; Cui X; Li W; Cai C; Xu J; Zhao X
    Cancer Immunol Res; 2019 Nov; 7(11):1813-1823. PubMed ID: 31484657
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adnectin-Based Design of Chimeric Antigen Receptor for T Cell Engineering.
    Han X; Cinay GE; Zhao Y; Guo Y; Zhang X; Wang P
    Mol Ther; 2017 Nov; 25(11):2466-2476. PubMed ID: 28784559
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adoptive Transfer of IL13Rα2-Specific Chimeric Antigen Receptor T Cells Creates a Pro-inflammatory Environment in Glioblastoma.
    Pituch KC; Miska J; Krenciute G; Panek WK; Li G; Rodriguez-Cruz T; Wu M; Han Y; Lesniak MS; Gottschalk S; Balyasnikova IV
    Mol Ther; 2018 Apr; 26(4):986-995. PubMed ID: 29503195
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Epitope-targeted cytotoxic T cells mediate lineage-specific antitumor efficacy induced by the cancer mucosa antigen GUCY2C.
    Snook AE; Magee MS; Marszalowicz GP; Schulz S; Waldman SA
    Cancer Immunol Immunother; 2012 May; 61(5):713-23. PubMed ID: 22057677
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Novel GUCY2C-CD3 T-Cell Engaging Bispecific Construct (PF-07062119) for the Treatment of Gastrointestinal Cancers.
    Mathur D; Root AR; Bugaj-Gaweda B; Bisulco S; Tan X; Fang W; Kearney JC; Lucas J; Guffroy M; Golas J; Rohde CM; Stevens C; Kamperschroer C; Kelleher K; Lawrence-Henderson RF; Upeslacis E; Yao J; Narula J; LaVallie ER; Fernandez DR; Buetow BS; Rosfjord E; Bloom L; King LE; Tchistiakova L; Nguyen A; Sapra P
    Clin Cancer Res; 2020 May; 26(9):2188-2202. PubMed ID: 31996389
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunological Synapse Predicts Effectiveness of Chimeric Antigen Receptor Cells.
    Xiong W; Chen Y; Kang X; Chen Z; Zheng P; Hsu YH; Jang JH; Qin L; Liu H; Dotti G; Liu D
    Mol Ther; 2018 Apr; 26(4):963-975. PubMed ID: 29503199
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combined Antitumor Effects of Sorafenib and GPC3-CAR T Cells in Mouse Models of Hepatocellular Carcinoma.
    Wu X; Luo H; Shi B; Di S; Sun R; Su J; Liu Y; Li H; Jiang H; Li Z
    Mol Ther; 2019 Aug; 27(8):1483-1494. PubMed ID: 31078430
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Modelling CAR-T therapy in humanized mice.
    Wu Y; Yu XZ
    EBioMedicine; 2019 Feb; 40():25-26. PubMed ID: 30665855
    [No Abstract]   [Full Text] [Related]  

  • 32. Preclinical assessment of transiently TCR redirected T cells for solid tumour immunotherapy.
    Mensali N; Myhre MR; Dillard P; Pollmann S; Gaudernack G; Kvalheim G; Wälchli S; Inderberg EM
    Cancer Immunol Immunother; 2019 Aug; 68(8):1235-1243. PubMed ID: 31214732
    [TBL] [Abstract][Full Text] [Related]  

  • 33. B7-H3-Targeting Chimeric Antigen Receptors Epstein-Barr Virus-specific T Cells Provides a Tumor Agnostic Off-The-Shelf Therapy Against B7-H3-positive Solid Tumors.
    Yeo SP; Kua L; Tan JW; Lim JK; Wong FH; Santos MD; Poh CM; Goh AX; Koh XY; Zhou X; Rajarethinam R; Chen Q; Her Z; Horak ID; Low L; Tan KW
    Cancer Res Commun; 2024 Jun; 4(6):1410-1429. PubMed ID: 38717140
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bispecific CAR T Cells against EpCAM and Inducible ICAM-1 Overcome Antigen Heterogeneity and Generate Superior Antitumor Responses.
    Yang Y; McCloskey JE; Yang H; Puc J; Alcaina Y; Vedvyas Y; Gomez Gallegos AA; Ortiz-Sánchez E; de Stanchina E; Min IM; von Hofe E; Jin MM
    Cancer Immunol Res; 2021 Oct; 9(10):1158-1174. PubMed ID: 34341066
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Development of a novel target module redirecting UniCAR T cells to Sialyl Tn-expressing tumor cells.
    Loureiro LR; Feldmann A; Bergmann R; Koristka S; Berndt N; Arndt C; Pietzsch J; Novo C; Videira P; Bachmann M
    Blood Cancer J; 2018 Aug; 8(9):81. PubMed ID: 30190468
    [No Abstract]   [Full Text] [Related]  

  • 36. Development of third generation anti-EGFRvIII chimeric T cells and EGFRvIII-expressing artificial antigen presenting cells for adoptive cell therapy for glioma.
    Sahin A; Sanchez C; Bullain S; Waterman P; Weissleder R; Carter BS
    PLoS One; 2018; 13(7):e0199414. PubMed ID: 29975720
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lenalidomide Enhances the Function of CS1 Chimeric Antigen Receptor-Redirected T Cells Against Multiple Myeloma.
    Wang X; Walter M; Urak R; Weng L; Huynh C; Lim L; Wong CW; Chang WC; Thomas SH; Sanchez JF; Yang L; Brown CE; Pichiorri F; Htut M; Krishnan AY; Forman SJ
    Clin Cancer Res; 2018 Jan; 24(1):106-119. PubMed ID: 29061640
    [No Abstract]   [Full Text] [Related]  

  • 38. Optimization of IL13Rα2-Targeted Chimeric Antigen Receptor T Cells for Improved Anti-tumor Efficacy against Glioblastoma.
    Brown CE; Aguilar B; Starr R; Yang X; Chang WC; Weng L; Chang B; Sarkissian A; Brito A; Sanchez JF; Ostberg JR; D'Apuzzo M; Badie B; Barish ME; Forman SJ
    Mol Ther; 2018 Jan; 26(1):31-44. PubMed ID: 29103912
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Chimeric Antigen Receptor T Cells With Modified Interleukin-13 Preferentially Recognize IL13Rα2 and Suppress Malignant Glioma: A Preclinical Study.
    Kim K; Gwak HS; Han N; Hong EK; Choi BK; Lee S; Choi S; Park JH; Seok JH; Jeon Y; Cho H; Lee SJ; Lee Y; Nam KT; Song SW
    Front Immunol; 2021; 12():715000. PubMed ID: 34819930
    [TBL] [Abstract][Full Text] [Related]  

  • 40. NK Cells Expressing a Chimeric Activating Receptor Eliminate MDSCs and Rescue Impaired CAR-T Cell Activity against Solid Tumors.
    Parihar R; Rivas C; Huynh M; Omer B; Lapteva N; Metelitsa LS; Gottschalk SM; Rooney CM
    Cancer Immunol Res; 2019 Mar; 7(3):363-375. PubMed ID: 30651290
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 66.